XNCR Xencor, Inc.

21.75
-0.38  -2%
Previous Close 22.13
Open 22.35
Price To book 3.40
Market Cap 1.02B
Shares 46,703,000
Volume 326,932
Short Ratio 7.00
Av. Daily Volume 244,246

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiated March 2016. Initial data due 2018 or early 2019.
XmAb5871
Systemic Lupus Erythematosus (SLE)
Phase 2 top-line data due in 2017.
XmAb5871
IgG4-Related Disease (IgG4-RD)

Latest News

  1. Worst-Performing Gurus' Stocks
  2. Xencor's Lead Drug Candidate, XmAb5871, Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease
  3. Edited Transcript of XNCR earnings conference call or presentation 9-May-17 8:30pm GMT
  4. Xencor reports 1Q loss
  5. Xencor Reports First Quarter 2017 Financial Results
  6. Investor Network: Xencor, Inc. to Host Earnings Call
  7. Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : May 9, 2017
  8. Xencor to Host First Quarter 2017 Financial Results Webcast and Conference Call on May 9, 2017
  9. Xencor, Inc. – Value Analysis (NASDAQ:XNCR) : April 26, 2017
  10. Xencor to Present at 42nd Annual Deutsche Bank Health Care Conference
  11. Xencor, Inc. breached its 50 day moving average in a Bullish Manner : XNCR-US : April 25, 2017
  12. Xencor Appoints Kevin Gorman, Ph.D., to its Board of Directors
  13. Increased Earnings Estimates Seen for Xencor (XNCR): Can It Move Higher?
  14. Xencor, Inc. breached its 50 day moving average in a Bullish Manner : XNCR-US : March 27, 2017
  15. Novartis (NVS) Announces Positive Data on Heart Failure Drug
  16. Xencor to Present at Oppenheimer 27th Annual Healthcare Conference
  17. Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : March 14, 2017
  18. Xencor Announces Bruce L.A. Carter, Ph.D., Chairman of the Board of Directors, Will Not Stand for Reelection to Board of Directors at 2017 Annual Meeting of Stockholders
  19. Xencor, Inc. :XNCR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 3, 2017
  20. Xencor Presents Preclinical Data on Emerging Bispecific Antibody Candidates at American Association for Cancer Research (AACR) 2017 Annual Meeting